U.S. deems Wyeth schizophrenia drug not approvable

U.S. health officials have determined that a schizophrenia drug developed by Wyeth and two other drugmakers is not approvable, the companies said on Friday, dealing Wyeth a second setback in a month on a product potentially close to the market.

And in another blow to Wyeth, its partner on an experimental hepatitis C drug, ViroPharma Inc., said on Friday that the companies were stopping a clinical trial of the medicine due to safety concerns.

READ MORE @ REUTERS